Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

Lilly Finalizes Acquisition of ImClone Systems

  • Eli Lilly and Company completed its acquisition of ImClone Systems today. ImClone Systems is now a wholly owned subsidiary of Lilly.

    "We are excited about the successful completion of the ImClone transaction, which will broaden Lilly's portfolio of marketed cancer therapies and boost Lilly's oncology pipeline with up to three promising targeted therapies in Phase III in 2009," said John Lechleiter, Ph.D., Lilly president and CEO.

    ImClone's CEO, John Johnson, will retain his current position at ImClone after the acquisition and will report directly to Lechleiter.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »